Shilpa Medicare Recalls Docetaxel Injection Due to Manufacturing Deviations
Shilpa Medicare Limited is recalling 2,008 vials of Docetaxel Injection USP due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. According to the severity rubric, an FDA Class II recall is assigned a score of 4 (Severe), as it represents a situation that might cause temporary or medically reversible adverse health consequences.
Plain-English summary
Shilpa Medicare Limited is voluntarily recalling 2,008 vials of Docetaxel Injection USP 160 mg/8mL (20 mg/mL). The product is distributed by Armas Pharmaceuticals, Inc., in Manalapan, New Jersey, and was distributed nationwide in the United States. The specific lot number is 7S10185A, with an expiration date of 10/31/2021.
The recall was initiated because of Current Good Manufacturing Practice (CGMP) deviations. The FDA has classified this recall as Class II, which indicates a situation that might cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Healthcare providers and patients should stop using the affected product. The recall was initiated on December 8, 2020, and was terminated on March 11, 2022.
The recalled product
- Product
- Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.
- Manufacturer
- Shilpa Medicare Limited
- Category
- Drug — Injection
- Hazard
- Affected units
- 2,008
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 7S10185A
- Exp. 10/31/2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 6 recalled by Shilpa Medicare Limited under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 6 products in this recall →Related recalls
Same manufacturer · Shilpa Medicare Limited
See all →- ModerateShilpa Medicare Recalls Discolored PEMRYDI RTU Injection Vials
FDA (Drugs) · 2026-08-26
- SevereShilpa Medicare Recalls Discolored Pemetrexed Injection Vials
FDA (Drugs) · 2026-08-26
- SevereFDA Recalls Imatinib Mesylate Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2020-12-16
- SevereShilpa Medicare Recalls Busulfan Injection Due to Manufacturing Deviations
FDA (Drugs) · 2020-12-16
- SevereShilpa Medicare Recalls Azacitidine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2020-12-16
Same hazard · cgmp deviations
See all →- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateDrug Recall: APAP 500 mg Phenyl HCl Tablets for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateMigrenol Caplet Drug Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16